EXCALIBER-RRMM

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jul 4, 2024 → Oct 13, 2026

Cited window

Jul 4, 2024 → Oct 13, 2026

Retrieved

Oct 18, 2026

Title

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)

Registry

NCT04975997

Study IDs

CC-220-MM-002 · U1111-1260-2872 (UTN Number) · 2020-000431-49

Sponsor

Celgene

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

939 actual

Start

2022-06-23 actual

Primary completion

2027-11-16 estimated

Primary endpoint

Progression-free Survival (PFS)

Interventions

8 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –Out of scope: 4 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –26 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed for this edition are a selected set of public and educational discussions, not a representative survey. Repeated recordings, related posts and account commentary cannot be counted as independent clinicians or used to estimate consensus.
• –The discussions span anticipation of results, MRD-based approval accounts, subsequent PFS reporting and publication-sharing. Their information states differ; dates and sequence alone do not establish that an individual changed position.
• –No full trial-results publication or trial protocol text is available for this report. A post sharing the manuscript does not supply its contents. Some speakers relied on press releases or prescribing information, so their numerical summaries and interpretations cannot be independently adjudicated here.
• –The regulatory material is incomplete, including the absence of an exact daratumumab label. Regulatory descriptions, approval timing and label-based implementation details remain attributed statements rather than independently confirmed regulatory conclusions.
• –Some potentially relevant recordings could not be read, and some passages could not be fully assessed. Discussion that used unnamed references or different spellings may also be missing.
• –Several recording voices could not be identified. Their views remain unnamed, and account posts or relayed recommendations are not treated as direct statements by an inferred individual.
• –The sources do not establish Mehak Trehan’s or Preetam Jain’s clinical role. Their posts are treated as attributed commentary, without assigning a specialty or practice setting.
• –Some source accounts differ about prior treatment, eligibility, regimen components, comparator wording, MRD assessment and adverse-event rates. Those differences are preserved rather than reconciled into a single factual description.
• –Cross-trial rankings are clinicians’ comparative interpretations, not head-to-head findings. Statements about other regimens retain their own population, setting, timing and supportive-care conditions.
• –Future combinations, bridging strategies, immune-enhancement hypotheses and maintenance proposals are not treated as established benefits or prescribing recommendations for the EXCALIBER-RRMM regimen.

How reports are built and checked: Methods.

Last checked for new commentary Oct 18, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.